Primary Sclerosing Cholangitis Epidemiology

Key Highlights

• In 2022, the US accounted for the maximum patient share in the 7MM, i.e., 57%, followed by EU4 and Japan.
• A particular challenge in assessing clinical symptoms in patients with PSC is the frequent concurrence of IBD, which itself can influence the clinical course of PSC and may also account for a significant proportion of symptoms, especially during periods of IBD exacerbations.
• In 2022, the diagnosed prevalent cases of Primary Sclerosing Cholangitis in Japan were 5% of the total diagnosed prevalent cases of the 7MM.
• It has been observed that a majority of patients are asymptomatic.

DelveInsight’s “Primary Sclerosing Cholangitis – Epidemiology – 2034” report delivers an in-depth understanding of Primary Sclerosing Cholangitis historical and forecasted epidemiology of Primary Sclerosing Cholangitis in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Primary Sclerosing Cholangitis Understanding

Primary Sclerosing Cholangitis Overview

According to the American Liver Foundation, primary sclerosing cholangitis (PSC) is a chronic or long-term disease that slowly damages the bile ducts. In PSC patients, the bile ducts are blocked due to inflammation and scarring or fibrosis, leading to the accumulation of bile in the liver, which gradually damages liver cells and causes cirrhosis or fibrosis of the liver. As cirrhosis progresses and the amount of scar tissue in the liver increases, the liver slowly loses its ability to function. The scar tissue may block the drainage of the bile ducts leading to bile infection.

Common initial symptoms of PSC are fatigue, abdominal discomfort, itching (pruritus), and obstructive jaundice. Additional symptoms include malaise, abdominal pain, nausea, dark urine, light-colored stools, unintended weight loss, and/or hepatomegaly and/or splenomegaly.

Primary Sclerosing Cholangitis Diagnosis

The diagnosis of PSC includes evaluation of patient history, clinical features, liver function tests (ALP, ?GT, ALT, bilirubin, albumin), blood tests, and the exclusion of differential diagnoses. Hepatobiliary system imaging techniques such as ultrasonography, ERCP, MRCP, MRC, and ultrasound are also employed. Sometimes, a liver biopsy is also required.

Further details related to diagnosis are provided in the report…

Primary Sclerosing Cholangitis

As the market is derived using a patient-based model, the Primary Sclerosing Cholangitis (PSC) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Diagnosed prevalent cases of Primary Sclerosing Cholangitis, Gender-specific diagnosed prevalent cases of Primary Sclerosing Cholangitis, Symptom-specific diagnosed prevalent cases of Primary Sclerosing Cholangitis, Comorbidity-specific diagnosed prevalent cases of Primary Sclerosing Cholangitis in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2021 to 2034.

• The diagnosed prevalent cases in the 7MM comprised approximately 53,081 cases in 2022 and are projected to increase during the forecast period (2025-2034).
• In the 7MM, the most diagnosed prevalent Primary Sclerosing Cholangitis cases were seen in the US, accounting for approximately 30,429 cases in 2022.
• Among EU4, Germany accounted for the highest number of Primary Sclerosing Cholangitis cases, whereas Spain accounted for the lowest number of cases in 2022.
• In Symptom-specific cases of Primary Sclerosing Cholangitis in 2022, the maximum number of cases were observed in the asymptomatic group.
• Males are more likely to get affected by Primary Sclerosing Cholangitis than females. In the UK, in 2022, around 3,088 male Primary Sclerosing Cholangitis cases were found.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on Primary Sclerosing Cholangitis’ evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including the Division of Hepatology Physicians and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as the David Geffen School of Medicine in Los Angeles, the US, University Hospital Aachen, Germany, and Tohoku University Hospital in  Sendai, Japan, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Primary Sclerosing Cholangitis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Scope of the Report

• The report covers a segment of critical events, an executive summary, and a descriptive overview of Primary Sclerosing Cholangitis (PSC), explaining its causes, signs and symptoms, pathogenesis, and current diagnostic algorithms.
• Comprehensive insight into the epidemiology segments and forecasts, disease progression, and diagnostic guidelines has been provided.
• The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journey in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Primary Sclerosing Cholangitis’ Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Gender-wise Cases of Primary Sclerosing Cholangitis
• Symptom-specific Cases of Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis Report Key Strengths

• Ten Years Forecast
• The 7MM Coverage
• Primary Sclerosing Cholangitis (PSC) Epidemiology Segmentation

Primary Sclerosing Cholangitis Report Assessment

• Current Diagnostic Practices

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Primary Sclerosing Cholangitis? What will be the growth opportunities across the 7MM concerning the patient population with Primary Sclerosing Cholangitis?
• What are the historical and forecasted Primary Sclerosing Cholangitis patient pools in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Which gender has a higher prevalence of Primary Sclerosing Cholangitis?
• Are symptomatic cases in Primary Sclerosing Cholangitis forming a major pool?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the Symptom-specific Primary Sclerosing Cholangitis prevalence cases in varying geographies over the coming years.
• A detailed overview of gender-specific cases of Primary Sclerosing Cholangitis is an inclusion.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the recurrent and treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.